Arwin Ridder

Randomized, double‐blind placebo‐ and tolterodine‐controlled trial of the once‐daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

Christopher R. Chapple, Tomasz Rechberger, P. J. MEFFAN et al. · British Journal of Urology · 2004 · 371 citations

Medicine, Pharmacology, Urology +15

RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF THE ONCE DAILY ANTIMUSCARINIC AGENT SOLIFENACIN SUCCINATE IN PATIENTS WITH OVERACTIVE BLADDER

L. Cardozo, M. LISEC, R. J. Millard et al. · The Journal of Urology · 2004 · 336 citations

Medicine, Pharmacology, Pharmacotherapy +17

Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)

Paul Abrams, Con Kelleher, David Staskin et al. · European Urology · 2014 · 247 citations

Medicine, Pharmacology, Pharmacotherapy +10

Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder ( <scp>SYNERGY</scp> study)

Christopher R. Chapple, Paul Abrams, Salvador Arlandis et al. · British Journal of Urology · 2017 · 174 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo‐ and tolterodine‐controlled phase 2 dose‐finding study

Christopher R. Chapple, Pedro Arañó, Jackie Bosch et al. · British Journal of Urology · 2003 · 169 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16